sa
gramposit
coccu
becom
ubiquit
colon
pathogen
healthcar
found
oropharyng
cultur
healthi
us
children
sa
even
common
sputum
sampl
patient
cf
gener
popul
preval
reach
peak
level
half
isol
sinc
howev
preval
specif
methicillinresist
aureu
mrsa
continu
increas
cf
patient
posit
sputum
cultur
mrsa
highli
concern
mrsaposit
sputum
cultur
associ
wors
pulmonari
function
well
increas
mortal
compar
patient
without
mrsa
also
evid
pathogen
synergi
exampl
pa
produc
virul
factor
pyocyanin
presenc
sa
pa
gramneg
rod
though
rare
found
healthi
individu
ubiquit
environ
common
seriou
pathogen
cf
patient
lead
reduc
lung
function
increas
mortal
histor
emerg
pa
major
pathogen
cf
center
part
led
develop
infect
prevent
control
clinic
care
guidelin
sputum
preval
pa
increas
age
rate
less
age
pa
thu
becom
major
caus
pulmonari
exacerb
adult
patient
pa
incred
adapt
de
novo
mutat
commonplac
pa
initi
clone
may
remain
clinic
appar
strain
mani
year
phenotyp
distinct
strain
develop
hidden
within
segreg
microcoloni
pa
virul
factor
also
chang
base
interact
host
bacteria
one
exampl
pa
increas
product
pyocyanin
expos
gramposit
bacteria
pa
seem
abl
adapt
specif
uniqu
environ
cf
lung
lung
epitheli
cell
secret
rel
lack
glutathion
cf
patient
caus
oxid
stress
environ
pa
respond
morph
mucoid
variant
hypersecret
mucoid
polysaccharid
call
algin
form
matrix
biofilm
structur
consortium
bacteria
polym
biofilm
shield
antimicrobi
well
host
immun
defens
phagocytosi
becom
quit
proinflammatori
trigger
host
humor
cellular
pathway
ultim
lead
lung
tissu
destruct
evad
effect
antibiot
pa
slow
doubl
time
thu
suscept
pa
also
directli
produc
toxin
strain
may
employ
impress
number
antibiot
resist
mechan
efflux
pump
sheer
virul
pa
mandat
continu
presenc
consid
chronic
infect
rather
simpli
colon
pa
infect
often
classifi
leed
criteria
base
pa
sputum
cultur
previou
year
patient
classifi
one
four
group
never
infect
pa
never
cultur
free
pa
growth
previou
month
intermitt
previou
month
pa
growth
chronic
cultur
posit
pa
last
month
categori
correl
clinic
outcom
never
free
group
experienc
least
sequela
chronic
group
experienc
fortun
preval
pa
cf
sputum
cultur
consist
decreas
last
year
children
posit
sputum
cultur
pa
number
decreas
like
due
increas
effort
erad
pa
first
posit
sputum
cultur
rate
posit
sputum
cultur
pa
decreas
time
rate
multidrug
resist
mdr
pa
remain
unchang
cf
popul
age
sustain
cumul
exposur
antibiot
antibiot
resist
emerg
burkholderia
cepacia
complex
bcc
group
gramneg
rod
caus
particularli
devast
clinic
cours
patient
cf
prior
burkholderia
spp
includ
pseudomona
genu
bcc
surviv
mani
environ
even
found
disinfect
bronchoscopi
equip
urinari
cathet
equip
ultrasound
gel
bcc
present
cf
patient
immunocompet
host
bcc
rel
avirul
howev
cf
patient
presenc
convey
wors
clinic
outcom
compar
pa
infect
bcc
associ
rapid
declin
bmi
b
cenocepacia
particular
associ
aggress
declin
burkholderia
cenocepacia
b
multivoran
common
strain
isol
cf
patient
classic
b
cenocepacia
associ
rapid
declin
b
multivoran
b
cepacia
isol
sent
cf
refer
librari
univers
michigan
patient
bcc
develop
lifethreaten
sometim
necrot
pneumonia
associ
bacteremia
sever
respiratori
failur
often
fatal
clinic
pictur
refer
cepacia
syndrom
one
fear
infecti
complic
cf
care
antibiot
resist
commonli
complic
treatment
nontubercul
mycobacteria
ntm
acidfast
bacilli
ubiquit
environ
commonli
found
soil
well
water
sourc
human
infect
usual
due
exposur
ntm
environ
rather
nosocomi
person
person
spread
ntm
preval
rise
cf
patient
gener
popul
patient
cf
ntm
sputum
posit
increas
patient
ntm
suffer
rapid
declin
pulmonari
function
control
patient
without
ntm
although
coinfect
sa
aspergillu
may
blame
compar
mycobacterium
avium
complex
mycobacterium
abscessu
complex
mabsc
difficult
erad
like
lead
death
lung
transplant
two
speci
make
ntm
seen
patient
cf
unfortun
mabsc
increas
ntm
stenotrophomona
maltophilia
gramneg
rod
found
young
adult
cf
patient
becom
recogn
organ
degre
pathogen
debat
studi
found
threefold
increas
death
lung
transplant
cf
patient
chronic
infect
maltophilia
howev
studi
attribut
observ
confound
factor
pancreat
insuffici
number
hospit
coinfect
pa
bcc
anoth
studi
show
serolog
respons
maltophilia
inde
independ
associ
pulmonari
exacerb
suggest
complex
role
host
respons
may
clinic
diseas
achromobact
xylosoxidan
gramneg
bacillu
inhabit
water
soil
found
cf
patient
clinic
impact
xylosoxidan
well
defin
time
chronic
infect
seem
induc
inflamm
declin
similar
patient
chronic
infect
pa
subset
chronic
infect
patient
high
achromobacterspecif
antibodi
declin
wors
still
howev
also
multipl
studi
found
signific
differ
bmi
cf
patient
xylosoxidan
microbiom
cf
patient
extend
far
beyond
bacteria
describ
loss
microbi
biodivers
associ
wors
lung
function
bacteria
haemophilu
influenza
anaerob
like
streptococcu
milleri
prevotella
actinomyc
veillonella
newer
bacteria
gemella
rothia
mucilaginosa
also
common
pathogen
anaerob
especi
interest
surviv
well
mucoid
surfac
biofilm
often
associ
wors
outcom
aspergillu
fumigatu
candida
albican
scedosporium
apiospermum
commonli
isol
fungi
cf
due
inabl
effect
clear
fungi
lower
respiratori
tract
cf
patient
often
colon
organ
caus
chronic
exposur
fungal
antigen
rather
caus
invas
pulmonari
diseas
fungi
may
caus
type
type
iii
hypersensit
reaction
increas
eosinophilia
ige
due
respons
commonli
studi
fungu
cf
patient
aspergillu
preval
aspergillu
spp
sputum
cultur
cf
patient
increas
age
well
worsen
lung
function
averag
aspergillu
colon
cf
patient
preval
rang
children
adult
unclear
whether
aspergillu
colon
associ
advers
outcom
howev
develop
allerg
sensit
aspergillu
associ
worsen
frequent
pulmonari
exacerb
allerg
bronchopulmonari
aspergillosi
abpa
clinic
phenomenon
occur
cf
patient
uniqu
cf
abpa
character
clinic
worsen
cough
wheez
declin
pulmonari
function
without
anoth
known
caus
diagnosi
abpa
requir
elev
total
ige
level
evid
allerg
sensit
aspergillu
either
posit
specif
ige
posit
skin
prick
test
find
may
includ
antiaspergillu
igg
peripher
eosinophilia
chest
imag
goal
manag
abpa
decreas
inflamm
eventu
fibrosi
occur
due
hypersensit
toward
continu
presenc
fungal
antigen
candida
speci
commonli
found
sputum
cultur
cf
patient
preval
high
chronic
colon
candida
associ
wors
outcom
studi
other
whether
neg
clinic
effect
attribut
candida
colon
remain
unclear
candida
colon
like
patient
diabet
patient
use
chronic
inhal
antibiot
steroid
patient
also
commonli
coinfect
infecti
pathogen
confound
like
effect
poor
lung
function
colon
candida
furthermor
contrast
aspergillu
allerg
sensit
candida
seem
caus
lung
function
declin
pulmonari
exacerb
fungi
often
colon
respiratori
tract
cf
patient
scedosporium
colon
cf
patient
usual
nonvirul
howev
posttranspl
immunosuppress
lead
pathogen
scedosporium
becom
invas
dissemin
potenti
deadli
unfortun
resist
mani
antifung
amphotericin
b
voriconazol
posaconazol
ravuconazol
drug
choic
may
even
use
combin
terbinafin
need
exophiala
dermatitidi
common
colon
cf
patient
frequent
found
adult
preferenti
colon
patient
pancreat
insuffici
colon
aspergillu
ntm
case
report
dissemin
diseas
noncf
immunocompromis
host
cf
gener
consid
benign
mani
respiratori
virus
associ
cf
exacerb
declin
pulmonari
exacerb
viral
compon
children
activ
pulmonari
exacerb
nearli
three
time
like
viral
infect
compar
near
baselin
biodivers
viral
infect
vari
age
geograph
locat
common
viral
infect
respiratori
syncyti
viru
rsv
influenza
b
viru
parainfluenza
viru
cytomegaloviru
cmv
human
rhinoviru
hrv
human
metapneumoviru
hmpv
coronaviru
adenoviru
across
age
spectrum
hrv
common
viral
infect
rsv
common
younger
patient
hmpv
older
pulmonari
exacerb
occur
frequent
winter
month
annual
emerg
influenza
respiratori
syncyti
viru
rsv
fig
unlik
bacteri
infect
cf
patient
increas
risk
viral
infect
similar
viral
respiratori
infect
unaffect
sibl
howev
cf
patient
contract
viral
infect
like
develop
lower
respiratori
tract
infect
expos
antibiot
declin
viral
infect
influenza
rsv
promot
bacteri
adher
enhanc
biofilm
format
increas
rate
lower
respiratori
tract
infect
annual
vaccin
influenza
strongli
recommend
help
prevent
diseas
complic
pandem
cf
patient
europ
test
posit
influenza
vaccin
rate
wherea
overal
vaccin
rate
cf
patient
estim
also
recommend
highrisk
cf
patient
four
exacerb
per
year
receiv
neuraminidas
inhibitor
prophylaxi
influenza
season
group
nearli
time
risk
pex
influenza
season
lower
risk
cf
patient
rsv
import
pathogen
children
although
seem
associ
pulmonari
exacerb
adult
rsv
associ
earli
pulmonari
declin
seem
increas
pa
antibiot
resist
enhanc
biofilm
product
rsv
infect
also
increas
risk
develop
chronic
pa
infect
increas
inflamm
patient
alreadi
chronic
infect
pa
much
interest
prevent
rsv
infect
pharmacolog
cf
patient
howev
palivizumab
monoclon
antibodi
rsv
antigen
seem
effect
decreas
rsv
relat
morbid
infant
cf
otherwis
meet
criteria
administr
rsv
vaccin
evalu
benefit
patient
cf
remain
establish
pulmonari
exacerb
decreas
lung
function
affect
qualiti
life
increas
mortal
histor
lack
consensu
definit
pex
retrospect
studi
pex
often
identifi
administr
intraven
antibiot
due
pulmonari
symptom
mani
criteria
suggest
includ
combin
follow
symptom
increas
sputum
volum
color
new
increas
hemoptysi
increas
cough
increas
dyspnea
malais
fatigu
temperatur
anorexiaweight
loss
sinu
pain
chang
sinu
discharg
chang
physic
examin
chest
decreas
pulmonari
function
radiograph
chang
support
pulmonari
infect
accord
stop
trial
gather
data
current
practic
across
cf
foundationaccredit
care
center
clinician
also
reli
acut
drop
lung
function
diagnos
pex
wellaccept
method
classifi
pex
sever
mani
biomark
consid
pex
diagnost
aid
date
none
perform
accept
well
clinic
use
procalcitonin
crp
gener
unhelp
predict
immin
exacerb
calprotectin
demonstr
earli
promis
abil
predict
pex
clinic
util
remain
unclear
matouk
et
al
show
patient
higher
hscrp
like
clinic
activ
diseas
futur
pex
biomark
panel
may
prove
use
singl
biomark
one
exampl
mrmm
protein
panel
compil
six
biomark
better
abl
identifi
patient
immin
pex
use
alon
pulmonari
exacerb
trigger
infect
environment
exposur
may
idiopath
acut
viral
infect
thought
contribut
half
exacerb
chronic
pulmonari
infect
gramneg
organ
pa
bcc
stenotrophomona
maltophilia
also
place
patient
high
risk
pex
without
obviou
precipit
well
understood
chronic
bacteri
colon
lead
pex
bacteri
overgrowth
new
resist
pattern
like
possibl
initi
approach
antimicrobi
therapi
usual
empir
inform
prior
sputum
cultur
antimicrobi
histori
supplement
oxygen
posit
pressur
ventil
intraven
rehydr
optim
nutrit
may
also
necessari
unfortun
best
practic
mani
aspect
pex
manag
remain
unclear
guidelin
cite
insuffici
evid
make
firm
recommend
regard
antibiot
rout
ie
addit
inhal
iv
antibiot
durat
antibiot
site
treatment
inpati
vs
home
therapi
system
steroid
ambigu
well
recogn
cf
provid
research
underway
bridg
gap
develop
standard
care
decis
admit
depend
patient
clinic
statu
well
home
resourc
home
util
caretak
avail
medic
administr
must
ensur
antibiot
monitor
pulmonari
therapi
often
much
easili
perform
inpati
set
sputum
sampl
often
grow
multipl
organ
studi
yet
elucid
best
antibiot
approach
occur
furthermor
resist
pattern
add
anoth
layer
biodivers
may
reflect
singl
sputum
sampl
nevertheless
isol
previou
patient
encount
assist
tailor
patientcent
approach
treatment
inform
local
antibiogram
patient
prior
current
sputum
cultur
recommend
regard
oral
versu
intraven
antibiot
therapi
patient
treat
intraven
antibiot
faster
improv
patient
treat
oral
antibiot
also
sicker
start
baselin
lung
function
european
guidelin
recommend
start
empir
oral
antibiot
cover
common
organ
includ
h
influenza
staphylococcu
ciprofloxacin
may
given
patient
prior
histori
pseudomona
despit
standard
use
inhal
antibiot
prevent
pex
inhal
antibiot
equival
intraven
antibiot
treatment
pex
stop
studi
also
found
larg
variat
length
antibiot
cours
prescrib
averag
day
rang
day
minimum
durat
day
recommend
antibiot
treatment
base
studi
found
patient
treat
day
less
increas
risk
requir
retreat
intraven
antibiot
next
day
accord
cff
patient
annual
report
notabl
patient
treat
outpati
set
ongo
studi
plan
focu
treatment
durat
implic
weigh
earli
relaps
improv
toxic
methicillinsensit
staphylococcu
aureu
treat
narrow
spectrum
betalactam
accord
local
antibiogram
mrsa
colon
treat
pex
accord
sensit
firstlin
therapi
mrsa
pex
vancomycin
linezolid
howev
antibiot
choic
individu
option
therapi
includ
trimethoprimsulfamethoxazol
doxycyclin
minocyclin
clindamycin
levofloxacin
teicoplanin
rifampin
note
vancomycin
penetr
biofilm
vancomycin
resist
also
confer
teicoplanin
resist
doxycyclin
typic
use
patient
less
year
old
linezolid
sever
potenti
side
effect
includ
serotonin
syndrom
irrevers
neuropathi
sever
lactic
acidosi
resist
linezolid
increas
use
frequent
center
often
cover
mrsa
clindamycin
trimethoprimsulfamethoxazol
vancomycin
depend
patient
histori
pseudomona
aeruginosa
preval
pathogen
contribut
disproportion
amount
lung
function
declin
mortal
often
two
antibiot
use
clinic
set
pa
cystic
fibrosi
foundat
state
insuffici
evid
support
combin
therapi
pa
certain
situat
especi
diseas
stage
mild
singl
therapi
may
use
two
antibiot
chosen
differ
mechan
action
combin
betalactam
aminoglycosid
tobramycin
frequent
use
oncedaili
dose
aminoglycosid
prefer
commonli
use
betalactam
cf
foundationaccredit
center
includ
ceftazidim
piperacillintazobactam
meropenem
cefepim
burkholderia
cepacia
complex
resist
aminoglycosid
frequent
betalactam
well
broad
spectrum
antibiot
includ
meropenem
piperacillintazobactam
aztreonam
ceftazidim
often
use
first
line
tetracyclin
ciprofloxacin
trimethoprimsulfamethoxazol
also
appropri
option
treatment
tailor
current
past
resist
bcc
pattern
signific
resist
cepacia
syndrom
appar
treatment
requir
multipl
antibiot
simultan
one
betalactam
studi
suggest
earli
treatment
prevent
chronic
bcc
colon
treatment
choic
stenotrophomona
maltophilia
trimethoprimsulfamethoxazol
plu
ticarcillinclavulan
levofloxacin
doxycyclin
tigecyclin
european
guidelin
recommend
cotrimoxazol
drug
choic
altern
includ
tetracyclin
ticarcillinclavulan
tigecyclin
primari
treatment
viralinduc
exacerb
support
care
monitor
secondari
bacteri
infect
neuraminidas
inhibitor
poorli
studi
cystic
fibrosi
although
efficaci
medic
question
nice
guidelin
recommend
patient
chronic
lung
diseas
treat
influenza
mainstay
treatment
allerg
bronchopulmonari
aspergillosi
abpa
corticosteroid
therapi
usual
prednison
mgkgd
week
follow
monthlong
taper
higher
dose
steroid
advers
effect
effect
addit
therapi
antifung
monoclon
antibodi
ige
may
necessari
nontubercul
mycobacteria
ntm
difficult
erad
requir
multidrug
therapi
recommend
treatment
cours
month
abscessu
notori
difficult
treat
high
rate
failur
recurr
despit
optim
therapi
treatment
abscessu
divid
initi
phase
last
week
continu
phase
continu
month
follow
three
neg
sputum
cultur
initi
phase
consist
azithromycin
intraven
amikacin
one
follow
tigecyclin
imipenem
cefoxitin
transit
continu
phase
patient
specif
depend
clinic
respons
continu
phase
consist
daili
azithromycin
inhal
amikacin
two
three
follow
minocyclin
clofazimin
moxifloxacin
andor
linezolid
avium
treatment
usual
success
oral
therapi
typic
azithromycin
plu
rifampin
ethambutol
macrolid
suscept
test
prior
start
treatment
avium
resist
recurr
case
although
antibiot
cornerston
treatment
pex
one
piec
care
receiv
respiratori
clearanc
treatment
chest
physiotherapi
crucial
function
improv
glucos
manag
also
import
especi
insulin
requir
increas
greatli
physiolog
stress
period
corticosteroid
therapi
steroid
use
treatment
pex
without
specif
indic
abpa
vari
result
literatur
therefor
current
recommend
cff
nutrit
optim
import
low
bmi
associ
worsen
prognosi
infect
increas
catabol
patient
year
older
undergo
regular
surveil
sputum
cultur
sensit
quarterli
ntm
cultur
annual
mrsa
presenc
confer
wors
clinic
outcom
cf
patient
optim
manag
remain
unclear
startoo
trial
found
erad
new
mrsa
infect
feasibl
newli
infect
cf
patient
may
suggest
longterm
clinic
benefit
treatment
protocol
includ
oral
antibiot
decolon
nasal
mupirocin
chlorhexidin
bodi
mouth
wash
enhanc
household
clean
howev
persist
infect
cf
patient
mrsa
erad
rate
remain
poor
even
addit
inhal
vancomycin
persist
mrsa
erad
protocol
pmep
trial
furthermor
inhal
vancomycin
caus
intoler
bronchospasm
patient
us
guidelin
await
evid
benefit
european
cystic
fibrosi
trust
recommend
aim
mrsa
erad
newli
infect
patient
nasal
mupirocin
chlorhexidin
bath
wash
either
combin
oral
therapi
rifampicin
fusid
acid
avail
us
nebul
vancomycin
combin
three
patient
becom
infect
pa
earli
erad
attempt
current
guidelin
recommend
inhal
tobramycin
mg
bid
day
attempt
erad
twentyeight
day
inhal
aztreonam
also
seem
effect
erad
strategi
newli
acquir
pa
inhal
colistin
oral
ciprofloxacin
firstlin
option
unit
kingdom
initi
colon
chronic
colon
pa
defin
three
posit
cultur
month
apart
ongo
inhal
aztreonam
tobramycin
recommend
treatment
patient
typic
administ
pattern
lastli
evid
ivacaftor
antipa
antisa
activ
due
quinolonelik
structur
explain
anoth
mechan
drug
efficaci
beyond
cftr
modul
current
guidelin
recommend
chronic
azithromycin
cf
patient
older
year
chronic
infect
pseudomona
due
signific
reduct
pex
infect
pa
chronic
azithromycin
use
purpos
although
evid
less
robust
one
concern
chronic
azithromycin
use
may
lead
resist
partial
treatment
ntm
present
reinforc
need
ntm
screen
least
annual
fig
cf
patient
gener
requir
larger
load
dose
antibiot
compar
gener
popul
suspect
due
lower
protein
bind
alter
volum
distribut
due
chronic
malnutrit
two
commonli
class
antibiot
prescrib
pex
antipseudomon
betalactam
aminoglycosid
interest
pharmacokinet
implic
although
betalactam
serum
drug
level
routin
measur
signific
chang
antibiot
clearanc
occur
pex
averag
increas
clearanc
result
betalactam
level
therapeut
time
seem
implic
airway
microbiom
howev
cf
foundat
state
guidelin
littl
evid
support
continu
infus
betalactam
antibiot
intraven
aminoglycosid
dose
daili
effect
thrice
daili
associ
less
renal
toxic
standard
practic
pediatr
cf
foundationaccredit
care
center
affili
program
monitor
aminoglycosid
serum
concentr
pex
tobramycin
typic
given
mg
kg
daili
initi
monitor
two
random
level
calcul
maximum
concentr
cmax
goal
cmax
mgl
trough
level
drawn
week
therapeut
dose
attain
period
monitor
crucial
tobramycin
clearanc
rate
decreas
averag
pex
creep
level
lead
nephrotox
ototox
bilater
lung
transplant
sens
cur
pulmonari
manifest
cystic
fibrosi
donor
lung
function
cftr
receptor
sustain
chronic
anatom
injuri
cf
bronchiectasi
howev
patient
continu
uniqu
infecti
risk
follow
transplant
preexist
organ
tend
find
way
transplant
lung
like
harbor
nontranspl
airway
space
sinus
organ
pa
tend
easili
treat
especi
burkholderia
cenocepacia
associ
reduc
surviv
may
consid
contraind
transplant
recept
lung
transplant
requir
lifelong
immunosuppress
carri
uniqu
infecti
diseas
consider
outsid
scope
text
patient
cf
acquir
infect
varieti
mean
direct
contact
infecti
secret
easili
avoid
indirect
contact
also
occur
via
fomit
stethoscop
contamin
surfac
object
disinfect
regularli
nebul
potenti
share
devic
reserv
singlepati
use
respiratori
virus
readili
travel
person
person
infecti
droplet
nuclei
spread
far
feet
respiratori
bacteri
pathogen
usual
pass
healthi
person
healthi
person
transmiss
patient
cf
increasingli
recogn
therefor
effort
taken
minim
close
interact
patient
cf
never
share
room
unless
alreadi
live
within
household
clinic
optim
flow
minim
patient
time
wait
room
common
area
rather
rotat
cf
patient
variou
area
clinic
staff
member
rotat
patient
singular
room
cf
patient
wear
surgic
mask
whenev
share
area
healthcar
set
hallway
restroom
howev
need
wear
mask
clinic
hospit
exam
room
healthcar
provid
wear
gown
glove
whenev
interact
patient
cf
whether
inpati
outpati
regardless
recent
cultur
result
provid
may
also
need
wear
appropri
mask
droplet
airborn
precaut
otherwis
indic
base
suspect
confirm
presenc
infecti
pathogen
ie
adenoviru
mycobacteria
etc
patient
provid
alik
alway
practic
meticul
frequent
hand
hygien
